ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer

Sunday, August 28, 2016

Submitted by

Mark Ferguson

Source

Source Name: Annals of Thoracic Surgery

Source URL: http://dx.doi.org/10.1016/j.athoracsur.2016.05.065

Author(s)

Paul J Speicher, Zachary W Fitch, Brian C Gulack, Chi-Fu J Yang, Betty C Tong, David H Harpole, Thomas A D'Amico, Mark F Berry, and Matthew G Hartwig

The authors tested the hypothesis that induction therapy improves survival in patients undergoing resection for clinical N1 disease using information from the National Cancer Data Base. 10% of over 5,000 pts were treated with induction therapy. They were 2:1 propensity matched with patients undergoing the traditional surgery first strategy. Among surgery first patients, 16% were overstaged (pN0) and 11% were understaged (pN2-3). There was no difference in short-term outcomes or survival between the two treatment groups.